LifeArc Ventures – strong performance in 2022 & sustained investment in innovation
- Wednesday, February 1, 2023, 7:12
- PR Newswire
- Add a comment
Highlights DJS Antibodies – portfolio company acquired by AbbVie for approx. $255 million in cash at closing plus potential future milestones, focused on novel antibodies against difficult-to-drug protein targets in immunology and beyond Ducentis BioTherapeutics – portfolio company…
About the Author
admin has written 21716 stories on this site.